Lipoprotein-Associated Phospholipase A 2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population

[1]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[2]  C. Meisinger,et al.  C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany , 2004, Circulation.

[3]  A. Dyer,et al.  Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. , 2003, JAMA.

[4]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[5]  A. Dyer,et al.  Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .

[6]  C. Packard,et al.  Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease , 2003, Current opinion in lipidology.

[7]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[8]  A. Tselepis,et al.  Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. , 2002, Atherosclerosis. Supplements.

[9]  R. Wolfert,et al.  Lp-PLA2: an emerging biomarker of coronary heart disease , 2002, Expert review of molecular diagnostics.

[10]  J. Manson,et al.  A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. , 2001, Journal of the American College of Cardiology.

[11]  S M Grundy,et al.  Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. , 2001, Circulation.

[12]  T. Kosaka,et al.  Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[13]  D. Tew,et al.  Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy. , 2001, Farmaco.

[14]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[15]  G. Lowe,et al.  Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. , 2000, Clinical chemistry.

[16]  C. Packard,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease , 2000 .

[17]  T. Häkkinen,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Yasuo Ikeda,et al.  Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. , 1999, Biochemical and biophysical research communications.

[19]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.

[20]  A. Döring,et al.  Leisure-time physical activity but not work-related physical activity is associated with decreased plasma viscosity. Results from a large population sample. , 1997, Circulation.

[21]  W. Kannel.  Range of serum cholesterol values in the population developing coronary artery disease. , 1995, The American journal of cardiology.

[22]  T. Imaizumi,et al.  Platelet-activating factor acetylhydrolase in plasma lipoproteins of healthy men and women. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[23]  G. Zimmerman,et al.  Human macrophages secret platelet-activating factor acetylhydrolase. , 1990, The Journal of biological chemistry.

[24]  H. Bang,et al.  Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein , and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities ( ARIC ) Study , 2004 .

[25]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[26]  U. Keil,et al.  Case finding, data quality aspects and comparability of myocardial infarction registers: results of a south German register study. , 1991, Journal of clinical epidemiology.

[27]  S Böthig,et al.  WHO MONICA Project: objectives and design. , 1989, International journal of epidemiology.

[28]  M. Kornitzer,et al.  The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international Collaboration , 1988 .